Chemotherapy of Locally Advanced or Metastatic Urothelial Cell Carcinoma: Monocentric Real-Life Data
Authors Fischer C, Hofmann R, Hegele A
Received 18 September 2019
Accepted for publication 28 January 2020
Published 26 June 2020 Volume 2020:12 Pages 5077—5084
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Professor Harikrishna Nakshatri
Christine Fischer, Rainer Hofmann, Axel Hegele
Department of Urology and Pediatric Urology, University Medical Center, Marburg, Germany
Correspondence: Christine Fischer
Department of Urology and Pediatric Urology, University Medical Center, Baldingerstraße, Marburg, Germany
Background/Aim: Up to 30% of all patients will present with an advanced or a metastatic stage (mUCC) at the moment of the initial diagnosis of urothelial cell carcinoma of the bladder (UCC). We investigated the numbers, the efficacy and toxicity of different chemotherapies for mUCC in daily practice and “real-life” conditions and evaluated them substance-specifically.
Patients and Methods: All patients with a mUCC, who were treated between January 1, 2006 and October 31, 2016 at the Department of Urology and Pediatric Urology at University Hospital Marburg (Germany), were retrospectively analyzed. We set the focus on demographic and tumor-specific data as well as on effectiveness, therapy sequences, and drug tolerance.
Results: Forty-one patients were identified. Of the 41 patients, 85.4% of the patients in first-line therapy received gemcitabine/cisplatin. A large proportion of 85.4% received a second-line therapy and 40% a third-line therapy due to progress or relapse. Median overall survival (mOS) was 18 months including all patients and increased up to 29.5 months in the cases of three therapy lines.
Conclusion: Our data reveal that chemotherapy of mUCC is effective and side effects are manageable in daily clinical practice.
Keywords: urothelial carcinoma, metastatic urothelial carcinoma, bladder cancer
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]